The 16 references in paper D. Goryachev V., Yu. Chernova V., N. Uvarova E., Д. Горячев В., Ю. Чернова В., Н. Уварова Е. (2018) “КОНЦЕПЦИЯ СЛОЖНЫХ НЕБИОЛОГИЧЕСКИХ ЛЕКАРСТВЕННЫХ СРЕДСТВ ПРИ РАЗРАБОТКЕ ВОСПРОИЗВЕДЕННЫХ ПРЕПАРАТОВ // NON-BIOLOGICAL COMPLEX DRUGS CONCEPT IN GENERIC DRUGS DEVELOPMENT” / spz:neicon:vedomostincesmp:y:2018:i:1:p:11-16

1
Barros PP. Pharmaceuticals policies in European countries. Adv Health Econ Health Serv Res. 2010; 22: 3–27.
(check this in PDF content)
2
Федеральный закон Российской Федерации от 12 апреля 2010 г. No 61-ФЗ «Об обращении лекарственных средств». [Federal Law of the Russian Federation of 12.04.2010, No. 61-FZ «On Circulation of Medicines» (In Russ.)] Available from: http://www.consultant.ru/ document/cons_doc_LAW_99350/
(check this in PDF content)
3
Солдатов АА, Авдеева ЖИ, Алпатова НА, Медуницын НВ, Киселевский МВ, Лысикова СЛ и др. Проблемы регистрации биологических неоригинальных лекарственных препаратов. БИОпрепараты. Профилактика, диагностика, лечение 2014; (4): 24–36. [Soldatov AA, Avdeeva ZhI, Alpatova NA, Medunitsyn NV, Kiselevsky MV, Lysikova SL, et al. The aspects of biosimilar marketing approval process. BIOpreparations. Prevention, Diagnosis, Treatment 2014; (4): 24–36 (In Russ.)]
(check this in PDF content)
4
Crommelin DJ, de Vlieger JS, Weinstein V, Muhlebach S, Shah VP, Schellekens H. Different pharmaceutical products need similar terminology. AAPS J. 2014; 16(1): 11–4.
(check this in PDF content)
5
Vlieger JS, Muhlebach S, Shah VP, McNeil SE, Borchard G, Weinstein V, et al. Non-Biological Complex Drugs (NBCDs) and their follow-on versions: time for an editorial section. GaBI J. 2015; 4(4): 167–70.
(check this in PDF content)
6
Schellekens H, Klinger E, Muhlebach S, Brin JF, Storm G, Crommelin DJ. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol. 2011; 59(1): 176–83.
(check this in PDF content)
7
Schellekens H, Stegemann S, Weinstein V, de Vlieger JS, Fluhmann B, Muhlebach S, et al. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J. 2014; 16(1): 15–21.
(check this in PDF content)
8
Шварц ГЯ, Раменская ГВ. Анализ причин практической невозможности создания генериков Копаксона. Химико-фармацевтический журнал 2012; 46(11): 24–9. [Shvarts GYa, Ramenskaya GV. Analysis of reasons for the impossibility of creating Copaxone generics. Pharmaceutical Chemistry Journal 2012; 46(11): 24–9 (In Russ.)]
(check this in PDF content)
9
Conner J. Glatiramer acetate and therapeutic peptide vaccines for multiple sclerosis. J Autoimmun Cell Resp. 2014; 1: 1–3.
(check this in PDF content)
10
Towfic F, Funt JM, Fowler KD, Bakshi S, Blaugrund E, Artyomov MN, et al. Comparing the biological impact of glatiramer acetate with the biological impact of generic. PLoS One 2014; 9(1): e83757.
(check this in PDF content)
11
Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product (EMA/CHMP/SWP/620008/2012). Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2015/03/WC500184922.pdf
(check this in PDF content)
12
Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed. 2012; 7: 49–60.
(check this in PDF content)
13
Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, et al. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products? Cancer Chemother Pharmacol. 2010; 66(6): 1173–84.
(check this in PDF content)
14
Draft guidance on doxorubicin hydrochloride. United States Food and Drug Administration. Available from: https://www.fda.gov/ downloads/Drugs/%E2%80%A6/Guidances/UCM199635.pdf
(check this in PDF content)
15
Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product (EMA/CHMP/806058/2009/Rev.02). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2013/03/WC500140351.pdf
(check this in PDF content)
16
Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product (EMA/CHMP/SWP/620008/2012). Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency. Available from: http:// www.ema.europa.eu/docs/en_GB/
(check this in PDF content)